Abstract

Amebiasis, caused by the protozoan parasite Entamoeba histolytica, remains a significant global health challenge, particularly in developing countries with poor sanitation infrastructure. Current treatment options primarily rely on Nitroimidazole drugs such as Metronidazole and Tinidazole, albeit concerns regarding drug resistance and adverse effects persist. Consequently, there is an urgent need for novel therapeutic interventions against this devastating disease. This abstract reviews recent advancements in drug development targeting E. histolytica. Nitazoxanide, with its ability to disrupt the pyruvate-ferredoxin oxidoreductase enzyme in the parasite, has emerged as a promising alternative. Additionally, aminoglycoside antibiotics like Paromomycin, which inhibit protein synthesis in the parasite, have demonstrated efficacy in combination therapy.